You just read:

Morphotek Announces Top-Line Results of a Phase III Study of Farletuzumab in Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer

News provided by

Morphotek Inc.

Jan 10, 2013, 06:30 ET